Pre-clinical pharmacology of moclobemide. A review of published studies.
The novel antidepressant, moclobemide, is a reversible inhibitor of monoamine oxidase (MAO) preferentially of monoamine oxidise-A (MAO-A); it emerged for study out of a series of lipid-lowering agents. In spite of its weak MAO-A inhibition in vitro, moclobemide is a potent inhibitor of MAO-A, in vivo; its in vivo activity is of short duration, in contrast to the extremely long-lasting inhibition, e.g. by tranylcypromine. Moclobemide only slightly potentiates the pressor effect of oral tyramine in freely moving rats, again in contrast to tranylcypromine; it is not anti-cholinergic and is free of hepatotoxicity. Published evidence on the preclinical pharmacology is reviewed.
Burkard
W P
WP
F. Hoffman-La Roche Ltd, Basel, Switzerland.
Da Prada
M
M
Keller
H H
HH
Kettler
R
R
Haefely
W
W
D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D006801:Humans; D007527:Isoenzymes / Q000097:blood*; D020912:Moclobemide; D008995:Monoamine Oxidase / Q000097:blood*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D014439:Tyramine / Q000494:pharmacology
D001549:Benzamides; D007527:Isoenzymes; D008996:Monoamine Oxidase Inhibitors; D008995:Monoamine Oxidase; D020912:Moclobemide; D014439:Tyramine